尧良清，医学博士，主任医师，教授，博士生导师

 广州医科大学附属妇女儿童医疗中心妇产科学科带头人，中国抗癌协会中西整合卵巢癌专委会副主任委员，上海市抗癌协会妇科肿瘤专委会副主任委员，曾任复旦大学附属妇产科医院妇瘤科主任。

【研究方向】

尤其擅长卵巢癌、宫颈癌、子宫内膜癌、外阴癌、阴道癌等妇科恶性肿瘤的微创手术、化疗、靶向及综合治疗。他所领衔的团队是国内少数可独立开展肝、肠、颈等全身转移病灶MDT切除的团队，对于晚期或复发卵巢癌的减灭术满意率接近90%，处于国际前沿水平。他专注于实施高难度的宫颈癌手术，包括盆腔廓清、LEER手术等并填补国内空白，挽救治疗晚期复发肿瘤患者。此外，他带领的广妇儿妇瘤团队陆续开展内膜癌前哨淋巴结显影、复杂腹膜后肿块切除、腹腔热灌注化疗、肝动脉介入栓塞、肿瘤免疫及靶向治疗等系列新技术。

【科研项目】

1)国家自然科学基金（NO.82473110）“卵巢癌MEOX1/SPHK1/S1P轴介导癌相关成纤维细胞激活促进淋巴结转移的作用及机制研究”。2025-2028，49万元，在研，主持

2)上海市申康促进市级医院临床技能与临床创新三年行动计划（2020-2022年）重大临床研究项目（SHDC2020CR2068B）“晚期卵巢癌分子及影像学评估指导下优化治疗方案的选择”。2020-2022，30万元，已结题，子课题负责人

3)复旦大学医联体：卵巢癌规范化诊治及临床适宜技术研究。2017-2019，已结题，主持

4)上海市申康适宜技术联合开发推广应用项目（SHDC12016240）髂内动脉灌注化疗在晚期卵巢癌患者中的应用。2016-2019，10万，已结题，主持

5)国家自然科学基金（NO.81571401）“ROCK抑制剂诱导条件性重编程颗粒细胞及其干化机制的研究”。2016-2019，63万元，已结题，主持

6)新疆自治区科技支疆项目（201591153）“多样性导向合成类天然小分子化合物在卵巢癌治疗中的应用”，2015-2017，20万元，已结题，主持

7)上海市卫生系统优秀学科带头人计划（No.13B122）“多样性导向合成类天然小分子化合物在卵巢癌治疗中的探索及应用”。2014- 2016， 45万元，已结题，主持

8)上海市科委基金项目（No. 124119a2900）“双基因修饰间充质干细胞栓塞肿瘤血管治疗上皮性卵巢癌的研究”。 2013- 2015，20万元，已结题，主持

9)上海市科委基金项目（No. 114119a2100）“子宫内膜异位症血管生成相关的分子分型及个性化治疗的研究”。2011- 2013，15万元，已结题，主持

10)上海市科委基金项目（No. 08ZR1401900）“缺氧状态下卵巢癌细胞向内皮细胞分化过程中microRNA作用的研究”。2008- 2010，15万元，已结题，主持

【代表性论文及著作】

1.期刊论文(仅列近5年，在SCI及核心等期刊发表论文35篇，其中SCI论文29篇）：

1)Yuan L, Dong X, Chen M, Yao L*. A Vascular Centered Surgical Approach to Radical Hysterectomy: Laparoscopic Anatomy of Pelvic Vascular System Revisited. J Minim Invasive Gynecol. 2023 Jun 13:S1553-4650(23)00237-6. doi: 10.1016/j.jmig.2023.06.006. (IF:4.1 Q1)

2)Dong X, Chen M, Yao L*. Laparoscopic infragastric omentectomy in surgery of gynecologic malignant tumor. Int J Gynecol Cancer. 2023 Feb 14:ijgc-2022-004123. (IF:4.661，Q1)

3)Dong X, Yuan L, Yao L*. Retrograde hysterectomy approach in a patient with a frozen pelvis due to a suspected ovarian malignancy. Int J Gynecol Cancer. 2023 Jan 3;33(1):128-129. (IF:4.661，Q1)

4)Wang Y#, Zhang H#, Wang T, Yao L, Zhang G, Liu X, Yang G*, Yuan L*. Deep learning for the ovarian lesion localization and discrimination between borderline and malignant ovarian tumors based on routine MR imaging. Sci Rep. 2023 Feb 16;13(1):2770.  (IF:4.996，Q2)

5)Luo X, Shen Y, Huang W, Bao Y, Mo J, Yao L, Yuan L. Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer. Cancer Control. 2023 Jan-Dec;30:10732748231159706. (IF:2.339，Q4)

6)邹若瑶,袁蕾,陈默, 尧良清*. 多次复发行3次及以上肿瘤细胞减灭术的卵巢上皮性癌患者预后及其影响因素分析[J]. 中华妇产科杂志,2023,58(3):198-206.

7)Zou R, Jiang Q, Jin T, Chen M, Yao L*, Ding H*. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer. Front Immunol. 2022 Aug 10;13:956224 (IF:8.786，Q1)

8)Luo X, Sun Y, Li J, Jiang Q, Yuan L, Li T, Chen M*, Yao L*. A durable response to programmed cell death 1 blockade in a multidrug-resistant recurrent ovarian cancer patient with HLA-B44 supertype: A case report. Front Immunol. 2022 Oct 6;13:951422. (IF:8.786，Q1)

9)Yi-Ting Bao #, Chao Wang #, Wu Huang, Liang-Qing Yao*, Lei Yuan*. A rare case of highly differentiated follicular carcinoma in ovary with FGFR4 Gly388Arg polymorphism: a case report and literature review. J Ovarian Res. 2022 Jun 14;15(1):71. doi: 10.1186/s13048-022- 01007-y (IF:5.506,Q1)

10)Zou R, Fu R, Abudousalamu Z, Yao L*. A rare extraperitoneal position of sigmoid colon during laparoscopic debulking surgery for ovarian tumor: Our operative experience. Asian J Surg. 2023 Mar 13:S1015-9584(23)00302-0. (IF:2.808，Q2)

11)Jiang Q, Chen M, Yuan L, Yao L*. Multidisciplinary procedures in the laparoscopic secondary cytoreductive surgery of advanced ovarian cancer. Int J Gynecol Cancer. 2022 Dec 5;32(12):1619-1620. (IF:4.661，Q1)

12)Jiang Q, Chen M, Yuan L, Yao L*. Multidisciplinary procedures in the laparoscopic secondary cytoreductive surgery of advanced ovarian cancer. Int J Gynecol Cancer. 2022 Dec 5;32(12):1619-1620. (IF:4.661，Q1)

13)Wu M, Zhao Y, Dong X, Jin Y, Cheng S, Zhang N, Xu S, Gu S, Wu Y, Yang J*, Yao L*, Wang Y*. Artificial intelligence-based preoperative prediction system for diagnosis and prognosis in epithelial ovarian cancer: A multicenter study. Front Oncol. 2022 Sep 21;12:975703. (IF:5.738，Q2)

14)Huang W, Bao Y, Luo X, Yao L, Yuan L*. Neuroendocrine neoplasms of the ovary: an analysis of clinicopathological characteristics and prognosis with a focus on histological grading. Endocrine. 2022 Jun;77(1):188-198. (IF:3.925，Q3)

15)Huang W, Bao Y, Luo X, Yao L, Yuan L*. Novel prognostic nomograms to assess survival in high-grade serous ovarian carcinoma after surgery and chemotherapy: a retrospective cohort study from SEER database. Ann Transl Med. 2022 Jul;10(13):728. (IF:3.616，Q3)

16)尧良清, 邹若瑶, 袁蕾, 等。扩大盆腔内侧壁切除术治疗晚期及复发妇科恶性肿瘤的临床病理分析[J]. 中华医学杂志, 2022, 102(26): 2026-2029.

17)Dan Ye, Haoran Shen, Wu Huang, Liangqing Yao*. A retrospective analysis of relapse-related factors for ovarian borderline tumors. Am J Transl Res. 2022 Aug 15;14(8):5712-5718. (IF: 3.940，Q3)

18)Li J, Sun Y, Zhi X, Li Q, Yao L*, Chen M*. The Expression and Role Analysis of Methylation-Regulated Differentially Expressed Gene UBE2C in Pan-Cancer, Especially for HGSOC. Cancers (Basel). 2022 Jun 25;14(13):3121. (IF: 6.575，Q1)

19)Yi-Ting Bao#, Chao Wang#, Wu Huang, Liang-Qing Yao*, Lei Yuan*. A rare case of highly differentiated follicular carcinoma in ovary with FGFR4 Gly388Arg polymorphism: a case report and literature review. J Ovarian Res. 2022 Jun 14;15(1):71. (IF:5.506, Q1)

20)Li J, Zhi X, Sun Y, Chen M*, Yao L*. The PDGF Family Is Associated with Activated Tumor Stroma and Poor Prognosis in Ovarian Cancer. Dis Markers. 2022 Sep 26;2022:5940049. (IF:3.464, Q2)

21)Bao Y, Huang W, Yao L, Yuan L*. Radical surgery for pseudo-ovarian malignancy: a case report of bowel endometriosis with massive ascites. Gland Surg. 2022 May;11(5):932-937. (IF:2.160, Q3)

22)Chen Mo, Li Jiajia, Yin Xiaojun, Yao Liangqing*. Laparoscopic radical pelvic dissection for safely removing a large cervical myoma. Int J Gynecol Cancer. 2021 Apr;31(4):633-634.（IF：3.44, Q2）

23)Dan Ye, Haoran Shen, Liangqing Yao*. A Study of Prognostic Factors of Chinese Patients with Gynecologic Tract Carcinosarcomas Prognosis of Gynecologic Carcinosarcomas. Cancer Manag Res. 2020; 12: 10781-8 (IF: 3.99, Q3)

24)Yiqun Zhang#, Jiajia Li#, Xuhui Dong, Dan Meng, Xiuling Zhi, Lei Yuan, and Liangqing Yao*. PSAT1 Regulated Oxidation Reduction Balance Affects the Growth and Prognosis of Epithelial Ovarian Cancer. OncoTargets and Therapy. 2020 11;13:5443-5453. ( IF：4.15，Q2)

25)Mo Chen#, Jia Zeng#, Shuyi Chen, Jiajia Li, Huijie Wu, Xuhui Dong, Yuan Lei, Xiuling Zhi*, Liangqing Yao*. SPTBN1 Suppresses the Progression of Epithelial Ovarian Cancer via SOCS3-mediated Blockade of the JAK/STAT3 Signaling Pathway. Aging (Albany NY) 2020.06.08 (IF:5.68，Q1)

26)Jiajia Li#, Xiuling Zhi, E12Shuyi Chen, Xiaoqing Shen, Chen Chen, Lei Yuan, Jieyu Guo, Dan Meng, Mo Chen*, Liangqing Yao*. CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer. Am J Cancer Res. 2020,10(4):1140-1155 (IF: 6.17，Q2)

27)Dong Xuhui#, Yuan Lei#, Yao Liangqing*. Recurrence of ovarian squamous cell carcinoma with MET gene copy number variation: a case report and review of literature. J Ovarian Res. 2020, 13(1):62 (IF:4.23，Q1)

28)Li J, Zhi X, Shen X, Chen C, Yuan L, Dong X, Zhu C, Yao L*, Chen M*. Depletion of UBE2C reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1. Biochem Biophys Res Commun. 2020 Mar 5;523(2):434-440. (IF:3.58，Q2)

29)Zhang H, Sun D, Qiu J, Yao L*. SFRP1 inhibited the epithelial ovarian cancer through inhibiting Wnt/β-catenin signaling. Acta Biochim Pol 2019 Nov 26;66(4):393-400 (IF；1.626，Q4)

30)Wenyan Han#, Yiqun Zhang#, Cong Niu#, Jieyu Guo, Jiajia Li, Xiangxiang Wei, Mengping Jia，Xiuling Zhi*, Liangqing Yao*, Dan Meng*. BTB and CNC homology 1 (Bach1) promotes human ovarian cancer cell metastasis by HMGA2-mediated epithelial-mesenchymal transition. Cancer Lett, 2019, 445: 45-56 (IF: 6.491，Q1)

31)张皓,尧良清*.老年卵巢癌的治疗[J].老年医学与保健,2019,25(03):288-291.

32)张皓,周跃华,尧良清*.曲妥珠单抗联合吉西他滨对卵巢癌小鼠移植瘤生长及免疫功能的影响[J].中国免疫学杂志,2019,35(05):608-612.

33)董戌晖,袁蕾,尧良清*.上皮性卵巢癌网膜切除术的研究进展[J].国际妇产科学杂志,2018,45(05):504-509.

34)Tong Gao, Yi Yu, Qing Cong, Yisheng Wang, Mingming Sun, Liangqing Yao, Congjian Xu, Wei Jiang*. Human mesenchymal stem cells in the tumor microenvironment promote ovarian cancer progression: the role of 5 platelet-activating factor. BMC Cancer. 2018, 19;18(1):999. (IF: 3.288， Q2)

35)李佳佳,陈默,尧良清*.基于循环肿瘤DNA的染色体不稳定性检测在卵巢癌中的研究进展[J].中国肿瘤,2018,27(07):521-524.

【学会任职】

中国抗癌协会中西整合卵巢癌专委会 副主任委员

中国医教协会微创手术专委会 副主任委员

上海市抗癌协会妇科肿瘤专委会 副主任委员

中国抗癌协会腹膜癌分会 委员

中国医促会妇产科分会 委员

中国医促会妇幼保健分会 委员

中国医师学会内镜分会妇科内镜分会 委员

上海市中医药学会生殖医学分会 委员

上海市妇产科医学分会肿瘤组成员 卵巢癌组副组长

《中华转移肿瘤杂志》副主编

《中国病理生理杂志》编委